Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014
Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014
复制标题
DOI：
10.1111/imj.12599
复制
发表时间：
2014-12-01
影响因子：
2.1
通讯作者：
Thursky, K. A.
中科院分区：
文献类型：
--
作者：
Cooley, L.;Dendle, C.;Thursky, K. A.
耶氏肺孢子虫感染（PJP）是癌症相关免疫抑制患者肺炎的常见原因。有明确定义的患者由于其基础恶性肿瘤、治疗相关免疫抑制和/或合并使用皮质类固醇而存在PJP风险。预防是非常有效的，应给予所有患者在中度至高度风险的PJP。甲氧苄啶-磺胺甲恶唑是预防和治疗的首选药物，尽管有几种替代药物可用。
Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. There are well-defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment-related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprim-sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.